Overview

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Status:
Terminated
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective, and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
Morphotek